Capital Advisors Inc Editas Medicine, Inc. Transaction History

Capital Advisors Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 25, 2021	SELL	$39.71 - $90.58 $4.76 Million - $10.9 Million	-119,833 Closed	0 $0
Q4 2020 Feb 08, 2021	SELL	$27.07 - $84.35 $2.15 Million - $6.7 Million	-79,443 Reduced 39.87%	119,833 $8.4 Million
Q3 2020 Nov 02, 2020	BUY	$28.06 - $37.16 $79,662 - $105,497	2,839 Added 1.45%	199,276 $5.59 Million
Q2 2020 Aug 07, 2020	BUY	$18.5 - $34.34 $137,973 - $256,107	7,458 Added 3.95%	196,437 $7.24 Million
Q1 2020 May 21, 2020	BUY	$14.88 - $32.78 $352,358 - $776,230	23,680 Added 14.33%	188,979 $3.75 Million
Q4 2019 Feb 04, 2020	BUY	$19.49 - $32.63 $550,105 - $920,981	28,225 Added 20.59%	165,299 $4.89 Million
Q2 2019 Aug 07, 2019	BUY	$20.48 - $27.76 $1.55 Million - $2.1 Million	75,782 Added 123.64%	137,074 $0
Q1 2019 May 10, 2019	SELL	$19.43 - $26.41 $1.43 Million - $1.95 Million	-73,743 Reduced 54.61%	61,292 $0
Q4 2018 Feb 06, 2019	BUY	$18.19 - $31.79 $242,545 - $423,887	13,334 Added 10.96%	135,035 $3.07 Million
Q3 2018 Nov 13, 2018	BUY	$27.65 - $38.39 $55,659 - $77,279	2,013 Added 1.68%	121,701 $3.87 Million
Q2 2018 Aug 06, 2018	SELL	$31.4 - $41.01 $128,300 - $167,566	-4,086 Reduced 3.3%	119,688 $0
Q1 2018 May 04, 2018	BUY	$29.84 - $44.08 $40,284 - $59,508	1,350 Added 1.1%	123,774 $0
Q4 2017 Jan 29, 2018	BUY	$21.89 - $31.34 $2.68 Million - $3.84 Million	122,424	122,424 $3.76 Million

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Capital Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Capital Advisors Inc with notifications on news.